A Phase 2 interventional study of Lenvatinib in Unresectable Stage III and Stage IV Melanoma, sponsored by Eisai Inc.. Completed at 95 sites in 4 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2019-11-13.
Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing lenvatinib in Melanoma — 3 open to participants now, 5 under way, none of them phase 3. lenvatinib · Melanoma.
Among the 18 studies testing lenvatinib in Melanoma, this one is the 3rd largest by enrollment, is one of 2 that started in 2010, is one of 12 in phase 2, and was the 3rd registered.
3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.
Browse Melanoma studies →3 of the 18 studies testing lenvatinib in Melanoma are open now, in 1 country. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18–75
Shanghai Zhongshan Hospital
Ages 18–75
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Sites in China
Ages 18–75
By country, each count listing its studies:
lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, lenvatinib is the treatment under test here. Read study by study →
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 15 · Phase 3 2
First in 2005; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 182 is above the median of 40 across 2,652 interventional studies indexed under Melanoma.
Median enrollment 41 across the 18 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 18 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
10 studies in Melanoma by Eisai Co., Ltd.: none open now, none under way, none of them phase 3. Of 10 finished, 6 (60%) have results posted.
Among the 10 studies in Melanoma by Eisai Co., Ltd., this one has the largest enrollment, is one of 5 that started in 2010, is one of 4 in phase 2, and was the 5th registered.
Eisai Co., Ltd.’s Melanoma studies by the year they started, since 2005.
1 of the studies testing lenvatinib in Melanoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03313206Gustave Roussy, Cancer Campus, Grand ParisNeoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing lenvatinib in Melanoma, from their registry updates:
Among Eisai Co., Ltd.’s 10 in Melanoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the objective response rate of lenvatinib in previously treated participants with American Joint Committee on Cancer (AJCC) unresectable Stage III or Stage IV melanoma and disease progression.
This was a Phase 2, multicenter, open-label, 2-cohort, 2-stage study that assessed the ORR of lenvatinib in previously treated participants with AJCC unresectable Stage III or Stage IV melanoma and disease progression. Cohort 1 enrolled participants not harboring the V600E BRAF mutation with disease progression following up to 2 prior systemic anticancer regimens (excluding anti-VEGF) for unresectable Stage III or Stage IV melanoma, and is referred to as Cohort 1 or V600E BRAF negative. Other less common BRAF activating mutations were allowed as long as the participant did not receive a BRAF-targeted therapy. Cohort 2 enrolled participants harboring the activating BRAF mutations (mainly the V600E mutation) with disease progression following BRAF V600E-targeted therapy, and is referred to as Cohort 2 or V600E BRAF positive. Eligible participants had measurable disease according to RECIST 1.1.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort 1 (V600E BRAF negative) enrolled participants not harboring the V600E BRAF mutation with disease progression following up to 2 prior systemic anticancer regimens (excluding anti-VEGF) for unresectable Stage III or Stage IV melanoma.
Drug: Lenvatinib
Cohort 2 (V600E BRAF positive) enrolled participants harboring the activating BRAF mutations (mainly the V600E mutation) with disease progression following BRAF V600E-targeted therapy.
Drug: Lenvatinib
Participants received lenvatinib 24 mg orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
Also known as: E7080
Objective Response Rate (ORR)
ORR, (ORR = CR + PR) was defined as the percentage of participants in each cohort who had a best overall response (BOR) of complete response (CR) or partial response (PR) based on Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 for target lesions assessed by magnetic resonance imaging/computed tomography (MRI/CT) scans and independent radiologic review (IRR). A BOR of CR required confirmation by a subsequent CR assessment at least 4 weeks later. A BOR of PR required confirmation by a subsequent assessment of CR or PR at least 4 weeks later. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to have a reduction in short axis to less than (\<)10 mm. PR was defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From date of treatment start until all participants completed a minimum of 6 cycles (28-day cycles) or discontinued treatment prior to end of Cycle 6 (up to 24 weeks)
Progression Free Survival (PFS)
PFS was measured as the time from the date of first administration of study treatment until the date of first documentation of disease progression or date of death from any cause (whichever occurred first), as determined by IRR and Investigator based on RECIST v1.1. Disease progression per RECIST v1.1 was defined as at least a 20% relative increase and 5 mm absolute increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions. PFS was analyzed using Kaplan-Meier (1958) product-limit estimates. Data were presented with 2-sided 95% confidence interval (CI) when an adequate number of at risk participants warranted the estimates in the table below.
Time frame: From date of treatment start until documentation of disease progression or death from any cause (whichever occurred first) or up to data cutoff (Cohort 1; 15 Jan 2012 and Cohort 2; 15 Apr 2013), up to approximately 2 years 8 months
Overall Survival (OS)
OS was defined as the length of time in months from the date of first administration of study drug until the date of death from any cause, and was based on the data cutoff date for each cohort. OS was analyzed using Kaplan-Meier (1958) product-limit estimates. Data were presented with 2-sided 95% CI when an adequate number of at risk participants warranted the estimates in the table below.
Time frame: From date of treatment start until date of death from any cause or up to data cutoff (Cohort 1; 15 Jan 2012 and Cohort 2; 15 Apr 2013), up to approximately 2 years 8 months
Disease Control Rate (DCR)
DCR, (DCR = CR + PR + SD) was defined as the percentage of participants who had a BOR of CR or PR or stable disease (SD) based on RECIST v1.1 for target lesions assessed by MRI/CT and IRR. CR was defined as the disappearance of all target lesions, any pathological lymph nodes (target or non-target) had to have a reduction in short axis to \<10 mm.; PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; Overall Response (OR) = CR + PR. SD defined as reduction in tumor volume of \< 30% or an increase in the volume of 1 or more measurable lesions of \< 25% without the appearance of any new lesions which was neither tumor shrinkage corresponding to PR nor tumor expansion corresponding to disease progression. BOR of SD, time from first administration of study drug until date of documented SD needed to be \>=7 weeks based on IRR and Investigator's assessment.
Time frame: From date of treatment start until documentation of disease progression or death from any cause (whichever occurred first) or up to data cutoff (Cohort 1; 15 Jan 2012 and Cohort 2; 15 Apr 2013), up to approximately 2 years 8 months
Clinical Benefit Rate (CBR)
CBR, (CBR = CR + PR + durable SD rate) was defined as the percentage of participants who had a BOR of CR or PR or durable SD (dSD, SD lasting \>=23 weeks) based on RECIST v1.1 for target lesions assessed by MRI/CT, IRR and Investigator's assessment. A BOR of CR required confirmation by a subsequent CR assessment at least 4 weeks later. A BOR of PR required confirmation by a subsequent assessment of CR or PR at least 4 weeks later. CR was defined as the disappearance of all target lesions, any pathological lymph nodes (target or non-target) had to have a reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; OR = CR + PR. A BOR of dSD, the time from the first administration of study drug until the date of documented dSD needed to be ≥23 weeks based on IRR and Investigator's assessment.
Time frame: From date of treatment start until documentation of disease progression or death from any cause (whichever occurred first) or up to data cutoff (Cohort 1; 15 Jan 2012 and Cohort 2; 15 Apr 2013), up to approximately 2 years 8 months
Number of Participants With Adverse Events (AEs)/ Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability of Lenvatinib
Safety was assessed by monitoring and recording all AEs including all Common Terminology Criteria for Adverse Events (CTCAE) grades and SAEs; regular monitoring of hematology, clinical chemistry, and urine values; physical examinations; and regular measurement of vital signs, electrocardiograms (ECGs), and multi-gated acquisition (MUGA) scans or echocardiogram.
Time frame: From date of treatment start up to 30 days after the last dose, or up to data cutoff (Cohort 1; 15 Jan 2012 and Cohort 2; 15 Apr 2013), up to approximately 2 years 9 months
Change From Baseline in the Concentration of Clinical Biomarkers in Whole Blood
Blood samples were drawn at specific time points. Utilizing a standard protocol, the deoxyribonucleic acid (DNA) from whole blood was extracted and analyzed for specific biomarkers of absorption, distribution, metabolism, and excretion of lenvatinib. Some of the biomarkers analyzed included; Angiopoietin, Epidermal Growth Factor (EGF), Fibroblast Growth Factor (FGF), FMS Like Tyrosine Kinase 3 Ligand (Flt3l) Granulocyte Colony Stimulating Factor (G-CSF), Granulocyte Macro Colony Stimulating Factor (GM-CSF), Interleukin 1 Receptor Antagonist (IL-1RA), Interferon (IFN), Macrophage Inflammatory Protein (MIP) 1 alpha, Platelet Derived Growth Factor (PDGF), Stromal Cell Derived Factor (SDF) 1 alpha, Interleukin (IL), Transforming Growth Factor (TGF), Tumor Necrosis Factor (TNF), Vascular Endothelial Growth Factor (VEGF).
Time frame: Cycle 1 Day 15 (C1 D15), Cycle 2 Day 1 (C2 D1), Cycle 3 Day 1 (C3 D1), Off-Treatment/Phase Visit 98 (V98)
Summary of Plasma Concentration of Lenvatinib
Blood samples for the quantification of lenvatinib in plasma were obtained and processed using a standardized protocol. The lower limit of quantification was 0.25 ng/mL. Pharmacokinetic (PK) analysis was conducted using nonlinear mixed effects modeling. Descriptive statistics were used to summarize lenvatinib plasma concentration data.
Time frame: Predose and 2 to 12 hours postdose at Cycle 1 Day 1 (C1D1), Cycle 1 Day 15 (C1D15), and Cycle 2 Day 1 (C2D1)
A total of 298 participants were screened. Of these, 116 were screen failures and 182 received treatment (93 participants in Cohort 1 and 89 participants in Cohort 2).
| Milestone | Cohort 1 (V600E BRAF Negative) | Cohort 2 (V600E BRAF Positive) |
|---|---|---|
| Started | 93 | 89 |
| Disease progression | 55 | 56 |
| Treatment ongoing at data cutoff | 14 | 6 |
| Completed | 69 | 62 |
| Not completed | 24 | 27 |
| Withdrew: Adverse event | 9 | 12 |
| Withdrew: Participant choice | 8 | 3 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Clinical progression | 3 | 5 |
| Withdrew: Radiation | 1 | 0 |
| Withdrew: Non-compliance | 1 | 0 |
| Withdrew: Investigator's choice | 1 | 1 |
| Withdrew: Increase in lesion size | 0 | 2 |
| Withdrew: Diagnosis of second primary cancer | 0 | 1 |
ORR, (ORR = CR + PR) was defined as the percentage of participants in each cohort who had a best overall response (BOR) of complete response (CR) or partial response (PR) based on Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 for target lesions assessed by magnetic resonance imaging/computed tomography (MRI/CT) scans and independent radiologic review (IRR). A BOR of CR required confirmation by a subsequent CR assessment at least 4 weeks later. A BOR of PR required confirmation by a subsequent assessment of CR or PR at least 4 weeks later. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to have a reduction in short axis to less than (\<)10 mm. PR was defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| Percentage of participants | Cohort 1 (V600E BRAF Negative) | Cohort 2 (V600E BRAF Positive) |
|---|---|---|
| Objective Response Rate (ORR) | 8.6 (3.8 to 16.2) | 9.0 (4.0 to 16.9) |
PFS was measured as the time from the date of first administration of study treatment until the date of first documentation of disease progression or date of death from any cause (whichever occurred first), as determined by IRR and Investigator based on RECIST v1.1. Disease progression per RECIST v1.1 was defined as at least a 20% relative increase and 5 mm absolute increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions. PFS was analyzed using Kaplan-Meier (1958) product-limit estimates. Data were presented with 2-sided 95% confidence interval (CI) when an adequate number of at risk participants warranted the estimates in the table below.
| Months | Cohort 1 (V600E BRAF Negative) | Cohort 2 (V600E BRAF Positive) |
|---|---|---|
| Determined by IRR | 3.7 (2.5 to 4.2) | 1.8 (1.8 to 2.2) |
| Determined by Investigator | 3.7 (3.6 to 4.2) | 2.3 (1.9 to 3.4) |
OS was defined as the length of time in months from the date of first administration of study drug until the date of death from any cause, and was based on the data cutoff date for each cohort. OS was analyzed using Kaplan-Meier (1958) product-limit estimates. Data were presented with 2-sided 95% CI when an adequate number of at risk participants warranted the estimates in the table below.
| Months | Cohort 1 (V600E BRAF Negative) | Cohort 2 (V600E BRAF Positive) |
|---|---|---|
| Overall Survival (OS) | 8.9 (8.3 to NA) | 6.3 (5.2 to 8.8) |
DCR, (DCR = CR + PR + SD) was defined as the percentage of participants who had a BOR of CR or PR or stable disease (SD) based on RECIST v1.1 for target lesions assessed by MRI/CT and IRR. CR was defined as the disappearance of all target lesions, any pathological lymph nodes (target or non-target) had to have a reduction in short axis to \<10 mm.; PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; Overall Response (OR) = CR + PR. SD defined as reduction in tumor volume of \< 30% or an increase in the volume of 1 or more measurable lesions of \< 25% without the appearance of any new lesions which was neither tumor shrinkage corresponding to PR nor tumor expansion corresponding to disease progression. BOR of SD, time from first administration of study drug until date of documented SD needed to be \>=7 weeks based on IRR and Investigator's assessment.
| Percentage of participants | Cohort 1 (V600E BRAF Negative) | Cohort 2 (V600E BRAF Positive) |
|---|---|---|
| Determined by IRR | 52.7 (42.1 to 63.1) | 34.8 (25.0 to 45.7) |
| Determined by Investigator | 64.5 (53.9 to 74.2) | 48.3 (37.6 to 59.2) |
CBR, (CBR = CR + PR + durable SD rate) was defined as the percentage of participants who had a BOR of CR or PR or durable SD (dSD, SD lasting \>=23 weeks) based on RECIST v1.1 for target lesions assessed by MRI/CT, IRR and Investigator's assessment. A BOR of CR required confirmation by a subsequent CR assessment at least 4 weeks later. A BOR of PR required confirmation by a subsequent assessment of CR or PR at least 4 weeks later. CR was defined as the disappearance of all target lesions, any pathological lymph nodes (target or non-target) had to have a reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; OR = CR + PR. A BOR of dSD, the time from the first administration of study drug until the date of documented dSD needed to be ≥23 weeks based on IRR and Investigator's assessment.
| Percentage of participants | Cohort 1 (V600E BRAF Negative) | Cohort 2 (V600E BRAF Positive) |
|---|---|---|
| Determined by IRR | 31.2 (22.0 to 41.6) | 14.6 (8.0 to 23.7) |
| Determined by Investigator | 33.3 (23.9 to 43.9) | 20.2 (12.4 to 30.1) |
Safety was assessed by monitoring and recording all AEs including all Common Terminology Criteria for Adverse Events (CTCAE) grades and SAEs; regular monitoring of hematology, clinical chemistry, and urine values; physical examinations; and regular measurement of vital signs, electrocardiograms (ECGs), and multi-gated acquisition (MUGA) scans or echocardiogram.
| Participants | Cohort 1 (V600E BRAF Negative) | Cohort 2 (V600E BRAF Positive) |
|---|---|---|
| AEs | 93 | 89 |
| SAEs | 39 | 36 |
Blood samples were drawn at specific time points. Utilizing a standard protocol, the deoxyribonucleic acid (DNA) from whole blood was extracted and analyzed for specific biomarkers of absorption, distribution, metabolism, and excretion of lenvatinib. Some of the biomarkers analyzed included; Angiopoietin, Epidermal Growth Factor (EGF), Fibroblast Growth Factor (FGF), FMS Like Tyrosine Kinase 3 Ligand (Flt3l) Granulocyte Colony Stimulating Factor (G-CSF), Granulocyte Macro Colony Stimulating Factor (GM-CSF), Interleukin 1 Receptor Antagonist (IL-1RA), Interferon (IFN), Macrophage Inflammatory Protein (MIP) 1 alpha, Platelet Derived Growth Factor (PDGF), Stromal Cell Derived Factor (SDF) 1 alpha, Interleukin (IL), Transforming Growth Factor (TGF), Tumor Necrosis Factor (TNF), Vascular Endothelial Growth Factor (VEGF).
| pg/mL | Cohort 1 (V600E BRAF Negative) | Cohort 2 (V600E BRAF Positive) |
|---|---|---|
| Angiopoietin 2 76 C1D15 | -1015.69 ± 946.596 | — |
| Angiopoietin 2 76 C2D1 | -832.29 ± 1257.287 | — |
| Angiopoietin 2 76 C3D1 | -923.82 ± 969.285 | — |
| Angiopoietin 2 76 V98 | -947.00 ± 825.037 | — |
| Angiopoietin 2 90 C1D15 | — | -1225.322 ± 1950.4525 |
| Angiopoietin 2 90 C2D1 | — | -1100.235 ± 1378.4621 |
| Angiopoietin 1 C1D15 | -3033.030 ± 8808.2059 | -2717.533 ± 16689.4536 |
| Angiopoietin 1 C2D1 | -2802.306 ± 10202.7814 | -1743.569 ± 15546.4804 |
| Angiopoietin 1 C3D1 | -859.021 ± 9994.6711 | — |
| Angiopoietin 1 V98 | 8107.400 ± 17740.0516 | — |
| Angiopoietin 2 C1D15 | -1462.552 ± 1541.8074 | -2154.269 ± 3560.0029 |
| Angiopoietin 2 C2D1 | -1225.462 ± 1872.5841 | -1884.439 ± 2357.1979 |
| Angiopoietin 2 C3D1 | -1255.485 ± 1738.0891 | — |
| Angiopoietin 2 V98 | -1374.183 ± 1158.2897 | — |
| CD40 Ligand C1D15 | -24020.778 ± 62788.2464 | -4678.661 ± 41191.7303 |
| CD40 Ligand C2D1 | -22957.613 ± 73677.4378 | -7254.754 ± 37794.5541 |
| CD40 Ligand C3D1 | -16700.900 ± 48016.0710 | — |
| CD40 Ligand V98 | 2192.177 ± 86909.9688 | — |
| EGF 2 C1D15 | -46.493 ± 101.0772 | -0.516 ± 219.9787 |
| EGF 2 C2D1 | -39.636 ± 125.0664 | -29.803 ± 121.1705 |
| EGF 2 C3D1 | -37.600 ± 113.8543 | — |
| EGF 2 V98 | -2.230 ± 191.4129 | — |
| EGF 59 C1D15 | -37.07 ± 81.051 | — |
| EGF 59 C2D1 | -31.58 ± 96.200 | — |
| EGF 59 C3D1 | -24.49 ± 93.102 | — |
| EGF 59 V98 | 10.17 ± 137.755 | — |
| EGF 80 C1D15 | — | -31.519 ± 126.2579 |
| EGF 80 C2D1 | — | -32.171 ± 121.7805 |
| Eotaxin-4 C1D15 | 51.456 ± 117.1266 | 46.538 ± 128.398 |
| Eotaxin-4 C2D1 | 99.974 ± 207.0243 | 60.919 ± 114.6134 |
| Eotaxin-4 C3D1 | 89.878 ± 108.6392 | — |
| Eotaxin-4 V98 | 104.613 ± 157.7527 | — |
| FGF 2 C1D15 | -4.294 ± 51.3985 | 8.325 ± 136.3433 |
| FGF 2 C2D1 | -8.085 ± 48.8273 | -8.003 ± 144.9054 |
| FGF 2 C3D1 | 7.443 ± 45.7310 | — |
| FGF 2 V98 | -3.917 ± 62.3623 | — |
| FGF 23 C1D15 | 6.549 ± 22.5297 | — |
| FGF 23 C2D1 | 6.496 ± 27.2305 | — |
| FGF 23 C3D1 | 6.691 ± 24.5203 | — |
| FGF 23 V98 | 13.430 ± 36.7130 | — |
| FGF 4 C1D15 | -24.226 ± 100.6823 | 50.369 ± 253.9626 |
| FGF 4 C2D1 | -15.491 ± 104.9991 | 55.785 ± 264.4585 |
| FGF 4 C3D1 | 5.283 ± 130.3452 | — |
| FGF 4 V98 | 33.860 ± 185.4616 | — |
| FGF Basic Form C1D15 | -0.597 ± 18.6851 | 43.457 ± 224.9856 |
| FGF Basic Form C2D1 | -1.212 ± 38.4131 | 64.237 ± 328.6676 |
| FGF Basic Form C3D1 | 2.060 ± 29.2405 | — |
| FGF Basic Form V98 | 18.384 ± 28.6214 | — |
| Flt3l C1D15 | -0.037 ± 32.5371 | -8.877 ± 23.0368 |
| Flt3l C2D1 | 5.135 ± 28.0359 | -1.362 ± 39.2251 |
| Flt3l C3D1 | 5.439 ± 24.1985 | — |
| Flt3l V98 | 13.367 ± 17.7279 | — |
| Fractalkine C1D15 | -11.700 ± 94.5115 | 38.670 ± 237.5045 |
| Fractalkine C2D1 | -1.175 ± 70.0858 | 4.663 ± 58.1950 |
| Fractalkine C3D1 | -5.588 ± 116.3955 | — |
| Fractalkine V98 | 15.838 ± 90.6004 | — |
| G-CSF C1D15 | 4.329 ± 20.8343 | 6.368 ± 61.7181 |
| G-CSF C2D1 | 7.366 ± 32.5552 | 12.601 ± 72.5113 |
| G-CSF C3D1 | 11.292 ± 24.1828 | — |
| G-CSF V98 | 34.653 ± 101.7055 | — |
| GM-CSF C1D15 | 0.767 ± 16.9314 | 44.665 ± 220.9124 |
| GM-CSF C2D1 | 4.371 ± 38.3355 | 139.491 ± 725.0903 |
| GM-CSF C3D1 | 10.036 ± 49.8538 | — |
| GM-CSF V98 | -1.495 ± 5.1831 | — |
| Growth Regulated Oncogene C1D15 | — | -141.838 ± 410.3579 |
| Growth Regulated Oncogene C2D1 | — | -120.148 ± 456.3073 |
| Hepatocyte Growth Factor C1D15 | 102.527 ± 1309.4077 | -91.790 ± 781.2225 |
| Hepatocyte Growth Factor C2D1 | -126.667 ± 693.2257 | -147.796 ± 411.1836 |
| Hepatocyte Growth Factor C3D1 | 61.257 ± 1062.3266 | — |
| Hepatocyte Growth Factor V98 | 404.700 ± 456.8130 | — |
| Interferon Gamma C1D15 | 4.072 ± 19.3994 | 33.743 ± 100.3678 |
| Interferon Gamma C2D1 | -0.392 ± 14.8083 | -10.164 ± 170.9869 |
| Interferon Gamma C3D1 | 2.986 ± 5.7591 | — |
| Interferon Gamma V98 | 2.455 ± 5.2255 | — |
| Interleukin 1 alpha C1D15 | 0.159 ± 7.9441 | 67.203 ± 200.9806 |
| Interleukin 1 alpha C2D1 | 0.226 ± 8.2728 | -36.352 ± 198.1416 |
| Interleukin 1 alpha C3D1 | -0.140 ± 13.7136 | — |
| Interleukin 1 Beta C1D15 | 0.279 ± 1.9668 | 59.768 ± 137.6657 |
| Interleukin 1 Beta C2D1 | 1.198 ± 5.0044 | 27.690 ± 61.2456 |
| Interleukin 1 Beta C3D1 | 1.882 ± 11.1737 | — |
| IL-1RA C1D15 | 14.490 ± 63.5869 | 46.381 ± 132.3985 |
| IL-1RA C2D1 | 20.295 ± 61.9799 | 38.131 ± 142.7521 |
| IL-1RA C3D1 | 7.048 ± 30.9383 | — |
| IL-1RA V98 | 84.614 ± 178.1590 | — |
| Interleukin 12 (p40) C1D15 | 14.514 ± 73.9806 | 5.458 ± 28.8514 |
| Interleukin 12 (p40) C2D1 | 16.052 ± 40.3849 | 918.03 ± 3917.8689 |
| Interleukin 12 (p40) C3D1 | 11.183 ± 36.3506 | — |
| Interleukin 12 (p40) V98 | -8.130 ± 5.7276 | — |
| Interleukin 12 (p70) C1D15 | 1.241 ± 18.8429 | 27.919 ± 62.8944 |
| Interleukin 12 (p70) C2D1 | -5.622 ± 28.6381 | 7.820 ± 71.1505 |
| Interleukin 12 (p70) C3D1 | -6.099 ± 19.5015 | — |
| Interleukin 12 (p70) V98 | 11.275 ± 20.0182 | — |
| Interleukin 10 C1D15 | -5.170 ± 38.0092 | -7.611 ± 22.1926 |
| Interleukin 10 C2D1 | -1.901 ± 33.6203 | 1.687 ± 72.7629 |
| Interleukin 10 C3D1 | 4.136 ± 10.8185 | — |
| Interleukin 10 V98 | -28.065 ± 41.7547 | — |
| Interleukin 13 C1D15 | 0.961 ± 5.0066 | 8.574 ± 13.4754 |
| Interleukin 13 C2D1 | 2.451 ± 7.6374 | 8.536 ± 18.5220 |
| Interleukin 13 C3D1 | 5.404 ± 16.4719 | — |
| Interleukin 15 C1D15 | 0.128 ± 2.2957 | 85.619 ± 234.7106 |
| Interleukin 15 C2D1 | 1.403 ± 4.1630 | 574.776 ± 1709.9272 |
| Interleukin 15 C3D1 | -0.178 ± 3.6993 | — |
| Interleukin 15 V98 | 3.930 ± NA | — |
| Interleukin 17 C1D15 | 3.434 ± 8.6463 | 4.567 ± 12.1008 |
| Interleukin 17 C2D1 | 1.264 ± 8.0963 | 3.035 ± 15.8736 |
| Interleukin 17 C3D1 | 0.011 ± 3.4100 | — |
| Interleukin 17 V98 | 8.440 ± 11.7663 | — |
| Interleukin 2 C1D15 | -1.004 ± 7.1024 | 173.878 ± 397.2754 |
| Interleukin 2 C2D1 | 5.853 ± 20.3294 | 191.410 ± 461.1991 |
| Interleukin 2 C3D1 | 2.647 ± 19.5979 | — |
| Interleukin 4 C1D15 | 8.169 ± 30.0305 | 12.815 ± 77.4310 |
| Interleukin 4 C2D1 | 20.167 ± 77.0619 | 7.815 ± 54.5735 |
| Interleukin 4 C3D1 | 6.583 ± 20.3824 | — |
| Interleukin 5 C1D15 | 0.311 ± 1.1314 | 6.088 ± 7.5239 |
| Interleukin 5 C2D1 | 0.205 ± 1.5931 | 11.382 ± 9.8663 |
| Interleukin 5 C3D1 | -0.327 ± 1.1102 | — |
| Interleukin 6 C1D15 | 0.166 ± 6.8774 | 3.784 ± 30.0715 |
| Interleukin 6 C2D1 | 4.778 ± 34.0254 | 5.524 ± 32.1205 |
| Interleukin 6 C3D1 | 2.027 ± 7.3121 | — |
| Interleukin 6 V98 | 3.160 ± 6.6276 | — |
| Interleukin 7 C1D15 | 1.267 ± 7.3732 | 2.167 ± 8.8122 |
| Interleukin 7 C2D1 | 2.413 ± 8.8367 | 5.744 ± 18.4339 |
| Interleukin 7 C3D1 | 0.616 ± 5.0590 | — |
| Interleukin 7 V98 | 20.760 ± 28.0439 | — |
| Interleukin 8 C1D15 | -5.801 ± 46.1572 | -20.769 ± 52.1135 |
| Interleukin 8 C2D1 | -5.431 ± 43.4197 | -14.303 ± 57.9561 |
| Interleukin 8 C3D1 | -7.348 ± 43.0509 | — |
| Interleukin 8 V98 | 26.982 ± 32.7795 | — |
| IFN gamma Induced Protein 10 C1D15 | 453.684 ± 1446.5825 | 184.891 ± 501.5782 |
| IFN gamma Induced Protein 10 C2D1 | 246.194 ± 246.194 | 306.075 ± 792.5621 |
| IFN gamma Induced Protein 10 C3D1 | 201.923 ± 483.5088 | — |
| IFN gamma Induced Protein 10 V98 | 359.872 ± 501.1082 | — |
| Monocyte Chemotactic Protein 1 C1D15 | 0.733 ± 423.2721 | -101.580 ± 371.5381 |
| Monocyte Chemotactic Protein 1 C2D1 | -19.036 ± 372.5242 | 128.749 ± 541.1034 |
| Monocyte Chemotactic Protein 1 C3D1 | 13.542 ± 370.3700 | — |
| Monocyte Chemotactic Protein 1 V98 | -128.627 ± 1234.5888 | — |
| MIP 1 alpha C1D15 | -1.842 ± 11.9129 | -0.320 ± 38.5273 |
| MIP 1 alpha C2D1 | -2.098 ± 12.0121 | -0.473 ± 35.4447 |
| MIP 1 alpha C3D1 | -1.167 ± 15.9038 | — |
| MIP 1 alpha V98 | 7.563 ± 7.8802 | — |
| MIP 1 beta C1D15 | 0.032 ± 20.1490 | 5.746 ± 64.1386 |
| MIP 1 beta C2D1 | -1.198 ± 31.4522 | 31.277 ± 261.3460 |
| MIP 1 beta C3D1 | 1.850 ± 15.208 | — |
| MIP 1 beta V98 | 7.518 ± 11.9566 | — |
| PDGF AA 31 P1 C1D15 | — | -183.36 ± 2260.110 |
| PDGF AA 31 P1 C2D1 | — | -268.83 ± 2054.666 |
| PDGF AB C1D15 | -36.637 ± 353.6898 | -121.278 ± 325.1308 |
| PDGF AB C2D1 | -99.852 ± 338.5816 | -80.778 ± 363.1249 |
| PDGF AB C3D1 | -7.702 ± 311.6834 | — |
| PDGF AB V98 | 130.800 ± 382.6282 | — |
| PDGF BB C1D15 | -120.317 ± 1758.7655 | -567.664 ± 1385.6740 |
| PDGF BB C2D1 | -435.311 ± 1961.7449 | -371.888 ± 1186.1 |
| PDGF BB C3D1 | 333.637 ± 1516.1506 | — |
| PDGF BB V98 | 174.083 ± 3221.9009 | — |
| Placental Derived Growth Factor C1D15 | 55.444 ± 55.0671 | 55.0671 ± 29.8457 |
| Placental Derived Growth Factor C2D1 | 50.439 ± 58.2571 | 51.359 ± 76.6390 |
| Placental Derived Growth Factor C3D1 | 61.080 ± 58.2969 | — |
| Placental Derived Growth Factor V98 | 112.683 ± 110.3416 | — |
| Chemokine Ligand 5 C1D15 | — | -2373.94 ± 46225.695 |
| Chemokine Ligand 5 C2D1 | — | 551.64 ± 49492.450 |
| SDF 1 alpha C1D15 | 441.305 ± 385.8988 | 506.768 ± 487.7603 |
| SDF 1 alpha C2D1 | 520.051 ± 510.8558 | 647.435 ± 470.0962 |
| SDF 1 alpha C3D1 | 509.483 ± 550.4383 | — |
| SDF 1 alpha V98 | 836.532 ± 686.4434 | — |
| Soluble IL2 Receptor alpha C1D15 | -25.869 ± 86.0991 | -414.669 ± 765.1544 |
| Soluble IL2 Receptor alpha C2D1 | -13.695 ± 65.5643 | -290.918 ± 1023.3392 |
| Soluble IL2 Receptor alpha C3D1 | -12.233 ± 31.5415 | — |
| Soluble IL2 Receptor alpha V98 | -19.238 ± 43.0942 | — |
| TGF alpha C1D15 | -0.874 ± 4.6605 | 21.148 ± 168.7766 |
| TGF alpha C2D1 | -0.350 ± 6.5375 | -6.019 ± 24.3258 |
| TGF alpha C3D1 | 1.165 ± 11.8825 | — |
| TGF alpha V98 | 2.590 ± 3.4672 | — |
| Tie-2 C1D15 | -2971.948 ± 2397.5234 | -3573.856 ± 2996.7139 |
| Tie-2 C2D1 | -3447.692 ± 3577.1791 | -4088.214 ± 3191.9812 |
| Tie-2 C3D1 | -2811.765 ± 3459.1934 | — |
| Tie-2 V98 | -1924.000 ± 3215.5684 | — |
| TNF alpha C1D15 | -0.233 ± 4.9747 | 1.451 ± 24.8216 |
| TNF alpha C2D1 | 0.039 ± 3.9540 | 1.741 ± 15.0677 |
| TNF alpha C3D1 | 0.614 ± 4.6336 | — |
| TNF alpha V98 | 3.027 ± 4.7343 | — |
| VEGF C1D15 | -13.294 ± 112.6871 | 10.709 ± 285.2533 |
| VEGF C2D1 | -11.523 ± 122.6064 | -26.215 ± 239.4960 |
| VEGF C3D1 | 16.732 ± 160.3096 | — |
| VEGF V98 | 155.638 ± 352.8309 | — |
| VEGF A C1D15 | 78.868 ± 174.8011 | 92.748 ± 273.6190 |
| VEGF A C2D1 | 76.041 ± 194.1394 | 140.664 ± 336.9135 |
| VEGF A C3D1 | 116.800 ± 233.1657 | — |
| VEGF A V98 | 465.833 ± 515.7676 | — |
| VEGF D C1D15 | 0.953 ± 87.6513 | 3.404 ± 42.7585 |
| VEGF D C2D1 | -9.776 ± 98.0905 | 11.043 ± 116.5445 |
| VEGF D C3D1 | 9.894 ± 57.1140 | — |
| VEGF D V98 | -21.317 ± 88.6689 | — |
| VEGF Rec 1 C1D15 | 593.613 ± 3109.3343 | -221.867 ± 799.9202 |
| VEGF Rec 1 C2D1 | -3.971 ± 739.7875 | -243.661 ± 1031.2376 |
| VEGF Rec 1 C3D1 | -209.863 ± 809.7744 | — |
| VEGF Rec 1 V98 | -15.567 ± 90.6274 | — |
| VEGF Rec 2 C1D15 | -10110.096 ± 5626.0125 | -8842.040 ± 6078.7151 |
| VEGF Rec 2 C2D1 | -9369.165 ± 17982.0625 | -10676.563 ± 7064.0825 |
| VEGF Rec 2 C3D1 | -11389.576 ± 10955.1596 | — |
| VEGF Rec 2 V98 | -9021.217 ± 5921.9619 | — |
| VEGF Rec 3 C1D15 | -1174.650 ± 2226.7893 | -2251.867 ± 3231.1485 |
| VEGF Rec 3 C2D1 | -1320.738 ± 3138.3810 | -2523.257 ± 3550.7291 |
| VEGF Rec 3 C3D1 | -1488.140 ± 3687.8774 | — |
| VEGF Rec 3 V98 | -1201.680 ± 2441.5741 | — |
Blood samples for the quantification of lenvatinib in plasma were obtained and processed using a standardized protocol. The lower limit of quantification was 0.25 ng/mL. Pharmacokinetic (PK) analysis was conducted using nonlinear mixed effects modeling. Descriptive statistics were used to summarize lenvatinib plasma concentration data.
| ng/mL | Cohort 1 (V600E BRAF Negative) | Cohort 2 (V600E BRAF Positive) |
|---|---|---|
| C1D1 Pre-dose | 0 ± 0 | 0 ± 0 |
| C1D1 Post-dose | 229.6 ± 148.98 | 287.6 ± 168.97 |
| C1D15 Pre-dose | 56.8 ± 82 | 71.9 ± 104.09 |
| C1D15 Post-dose | 284.0 ± 141.71 | 332.1 ± 221.98 |
| C2D1 Pre-dose | 38.7 ± 32.94 | 52.0 ± 48.73 |
| C2D1 Post-dose | 244.5 ± 182.67 | 270.4 ± 143.64 |
Collected over From date of administration of first dose up to 30 days after the last dose, or up to data cutoff (15 Jan 2012 and 15 Apr 2013 for Cohort 1 and Cohort 2, respectively), up to approximately 33 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 (V600E BRAF Negative) | — | 39/93 (41.9%) | 93/93 (100%) |
| Cohort 2 (V600E BRAF Positive) | — | 36/89 (40.4%) | 88/89 (98.9%) |
| Event | Cohort 1 (V600E BRAF Negative) | Cohort 2 (V600E BRAF Positive) |
|---|---|---|
| HypertensionVascular disorders | 5/93 | 1/89 |
| NauseaGastrointestinal disorders | 3/93 | 3/89 |
| Abdominal painGastrointestinal disorders | 1/93 | 3/89 |
| Deep vein thrombosisVascular disorders | 3/93 | 0/89 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 3/93 | 2/89 |
| PneumoniaInfections and infestations | 2/93 | 2/89 |
| Groin painMusculoskeletal and connective tissue disorders | 0/93 | 2/89 |
| FatigueGeneral disorders | 0/93 | 2/89 |
| General physical health deteriorationGeneral disorders | 0/93 | 2/89 |
| PancreatitisGastrointestinal disorders | 2/93 | 0/89 |
| Event | Cohort 1 (V600E BRAF Negative) | Cohort 2 (V600E BRAF Positive) |
|---|---|---|
| FatigueGeneral disorders | 62/93 | 41/89 |
| HypertensionVascular disorders | 53/93 | 48/89 |
| NauseaGastrointestinal disorders | 48/93 | 36/89 |
| DiarrhoeaGastrointestinal disorders | 44/93 | 26/89 |
| Decreased appetiteMetabolism and nutrition disorders | 40/93 | 30/89 |
| VomitingGastrointestinal disorders | 36/93 | 32/89 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 26/93 | 33/89 |
| ConstipationGastrointestinal disorders | 25/93 | 28/89 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 29/93 | 20/89 |
| HeadacheNervous system disorders | 29/93 | 21/89 |
| Age, Continuous(Years) | Cohort 1 (V600E BRAF Negative) | Cohort 2 (V600E BRAF Positive) | Total |
|---|---|---|---|
| Mean | 62.5 ± 11.71 | 55.0 ± 14.18 | 58.8 ± 13.47 |
| Sex/Gender, Customized(Participants) | Cohort 1 (V600E BRAF Negative) | Cohort 2 (V600E BRAF Positive) | Total |
|---|---|---|---|
| Female | 29 | 39 | 68 |
| Male | 64 | 50 | 114 |
| AJCC Melanoma Tumor, Node, Metastasis (TNM) Stage at Study Entry(Participants) | Cohort 1 (V600E BRAF Negative) | Cohort 2 (V600E BRAF Positive) | Total |
|---|---|---|---|
| Unresectable Stage III | 5 | 7 | 12 |
| Unresectable Stage IV | 88 | 82 | 170 |
Ran from Aug 2010 to primary completion in Apr 2013, 32 months.
Results were first posted in Mar 2016, 2 years 11 months after primary completion.
Of 106 industry-sponsored phase 2 interventional studies under Melanoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's 32 months is close to that.
Counting every sponsor, half of 383 studies reached it within 53 months; a quarter within 32 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenvatinib